PharmaTher Holdings Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PHRM.CN | 18H0.F | SILO | ENSC | HRTX | OCUL | |
|---|---|---|---|---|---|---|
| Market cap | 4.55M | 5.11M | 2.93M | 7.19M | 56.69M | 1.57B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.5 | — | -1.9 | -7.4 | -2.7 | -4.8 |
| Price/book | 7.1 | -1.1 | 0.3 | -7.7 | 9.6 | 3.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −52.38% | −25.00% | −83.17% | −82.13% | −72.73% | −32.83% |
| Today | −16.67% | −23.81% | +3.91% | −2.12% | +4.88% | +4.69% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PHRM.CN news ›PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Potential U.S. peptide reclassification and possible inclusion of select peptides on the Section 503A Bulks List could create a timely opportunity for MEDBOTX™ in compounding pharmacies, hospitals and personalized medicine settings Figure…
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on personalized medicines, today provided a corporate…
PharmaTher Builds Portfolio of Personalized, 3D-Printed Peptide Products for New U.S. Peptide Pathway, Led by Colon-Targeted KPV and BPC-157
BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe.…
PharmaTher Submits Orphan Drug and Rare Pediatric Disease Designation Applications to FDA for 3D-Printed Creatine Monohydrate in GAMT Deficiency
Lead FDA-track program targets a serious pediatric disease with no FDA-approved treatment and could qualify for a transferable priority review voucher. Highlights Two FDA designation applications submitted for creatine monohydrate in…
PharmaTher Builds Network of 3D Printing Nodes for Rare Disease, Shortage and Emergency Medicines
Home - PharmaTher Builds Network of 3D Printing Nodes for Rare Disease, Shortage and Emergency Medicines Where is AI unlocking advantages? Explore what is possible at AMA: Software 2026. One Formulation, Any Dose According to the company,…
PharmaTher Holdings Ltd. (OTCMKTS:PHRRF) Stock Short Interest Drops 83.7%
Posted by Michael Walen on Oct 10th, 2026 PharmaTher Holdings Ltd. (OTCMKTS:PHRRF – Get Free Report) was the target of a large drop in short interest in September. As of September 30th, there was short interest totaling 5,771 shares, a…
PharmaTher Plans U.S. Network to 3D Print Medicines on Demand
3DP/AM Market Insights: Q1 2026 3DP/AM Market Insights: Q2 2026 PharmaTher Plans U.S. Network to 3D Print Medicines on Demand 3D printing medicines has often been tied to the idea of personalization, basically making a pill in the right…
PharmaTher sets out CraftMake placement plan, renames platform M3DICINES
PharmaTher Holdings Ltd. has outlined plans to place up to 50 CraftMake pharmaceutical 3D printers across North America over the next 12 months, with initial orders expected in the fourth quarter of 2026. The Toronto-based company holds…
PharmaTher Launches M3DICINES National Network Program to Provide 3D-Printed Medicines for Rare Diseases, Discontinued Medicines, Drug Shortages and National Emergencies
The network is designed to bring together pharmacies, hospitals, contract manufacturers and government facilities to make personalized, rare disease, discontinued and short-supply medicines and emergency countermeasures, close to the…
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026. Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.financialcontent.com3
- 3dprint.com2
- investingnews.com2
- 3dprintingindustry.com1
- biospace.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.